Connect with us

Medical Discovery

NHK Documentary – Meltdown: Cooling Water Crisis [1080p]

Published

on



Recently discovered data show that about a week after the March 2011 disaster at the Fukushima Daiichi Nuclear Power Plant began, emissions of highly radioactive substances suddenly picked up. Records show that the day before the increase began, the plant’s operator, Tokyo Electric Power Company (TEPCO), significantly reduced the supply of water meant to cool the crippled reactors, a move that may triggered the surge in emissions. With help from experts and artificial intelligence, we set out to uncover the reason for the cutback, and to further clarify what happened as TEPCO and the Japanese government fought to control the crisis.

Continue Reading
2 Comments

2 Comments

  1. Man Lil

    May 26, 2018 at 4:35 pm

    Aaah so they basically cut cost at the worst places. Then now a lot of back and forth between employees while higher ups walks away scott free as usual.

  2. Gary Itano

    May 29, 2018 at 11:39 pm

    Note, at :22 & at program end, the steam coming out of Unit 2. This was due to the Unit 2 workers' heroic decision to follow their knowledge of physics & countemand "management's" incorrect decision to avoid venting contaminants into the atmosphere in favor of risking the inevitable explosion from the exceedingly high pure hydrogen gas buildup and, not only magnitudes greater venting, but damage to the storage pools, piping & other vital infrastructure within the secondary containment structure. Note also, "official" suppression of these facts immediately after videos of the panels being removed were originally broadcast. All (in the nuclear industry) is not always what they (are made to) seem. (Comment by the lead cybersecurity engineer for San Onofre Nuclear Generating Station, CA 2000-2013.)

Leave a Reply

Your email address will not be published. Required fields are marked *

Medical Discovery

IDZ Weekly | Deep Neural Network Acceleration for Image Analysis in Drug Discovery | Intel Software

Published

on

By



Learn about a recent collaboration with Novartis Pharmaceuticals, which utilizes a deep neural network to accelerate image analysis in early drug discovery by detecting and targeting exactly which cells in the body need treatment.

Read the article:

Keep up to date with the IDZ Weekly Youtube Playlist:

Subscribe to the Intel Software YouTube Channel:

About Intel Software:
The Intel® Developer Zone encourages and supports software developers that are developing applications for Intel hardware and software products. The Intel Software YouTube channel is a place to learn tips and tricks, get the latest news, watch product demos from both Intel, and our many partners across multiple fields. You’ll find videos covering the topics listed below, and to learn more, you can follow the links provided!

Connect with Intel Software:
Visit INTEL SOFTWARE WEBSITE:
Like INTEL SOFTWARE on FACEBOOK:
Follow INTEL SOFTWARE on TWITTER:

INTEL SOFTWARE GITHUB:
INTEL DEVELOPER ZONE LINKEDIN:
INTEL DEVELOPER ZONE INSTAGRAM:
INTEL GAME DEV TWITCH:

IDZ Weekly | Deep Neural Network Acceleration for Image Analysis in Drug Discovery | Intel Software

Continue Reading

Medical Discovery

Virtual Recap Preview: Stanford Drug Discovery Symposium 2018 – Joao Monteiro, MD, PhD

Published

on

By



Virtual Recap: Stanford Drug Discovery 2018
Learn more:

On April 23-24,2018 over 550 people gathered at the Li Ka Shing Conference Center to attend the Third Annual Stanford Drug Discovery Symposium. The event featured a broad range of speakers sharing their expertise in the fields of: academic drug discovery, academic-industry collaboration, science policy, publishing, and research funding. On the first day, the packed-house audience was treated to presentations from academic scientists engaged in groundbreaking research that is laying the foundation for future therapeutic approaches. These included Stanford based Nobel Laureate Brian Kobilka, MD and Edgar Engleman, MD; Kathleen Giacomini, PhD, and Kevan Shokat, PhD from UCSF; and Hugh Rosen, MD, PhD, from the Scripps Research Institute.

Later that afternoon, attendees had the rare opportunity to interact with six top pharmaceutical executives and philanthropists: Ken Frazier, CEO of Merck; Robert Bradway, CEO of Amgen; Joseph Jimenez, former CEO of Novartis; Brent Saunders, CEO of Allergan; Patrick Soon-Shiong, MD, CEO of Nantworks; and Sanford Weill, the Chairman Emeritus of Citigroup and CEO of Casa Rosa Ventures. In this “View from the Top” session moderated by Stanford President Marc Tessier-Lavigne, PhD, the panelists offered their perspectives on drug discovery, including: the future of personalized medicine, the importance of focusing on disease prevention rather than treatment, and the concept that drug pricing could eventually be based on treatment outcomes. The first day ended with the presentation of a Lifetime Achievement Award to Roy Vagelos, MD, former CEO of Merck and current Board chair of Regeneron. Dr. Vagelos was acknowledged in part for his role in leveraging the power of the pharmaceutical industry to make a major impact on global health. During his term as Merck CEO, he personally committed to providing the drug Ivermectin free of charge to anyone in the world for the treatment of elephantiasis and river blindness, with the latter having been since eradicated in multiple Central and South American countries due to Dr. Vagelos’ efforts.

The second day of the Symposium opened with a Keynote address from Janet Woodcock, MD, the Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA), who provided a look inside the agency’s new drug regulatory program. This was followed by important presentations about funding priorities from Gary Gibbons, MD, the Director of the National Heart, Lung, and Blood Institute (NHLBI), and Maria Millan, MD, President and CEO of the California Institute for Regenerative Medicine (CIRM). Later, the audience was treated to a panel of editors representing the top publications in biomedical science: the New England Journal of Medicine, Nature Medicine, Science, and the Journal of the American Medical Association. The meeting concluded with a dynamic Shark Tank-style session, in which representatives from eight competitively selected start-up biotechnology companies pitched their ideas to a panel of scientists, venture capitalists, and CEOs. The panelists who provided feedback were: George Scangos, PhD (CEO of Vir), Robert Robbins, MD (President of the University of Arizona), Roy Vagelos, MD, Amy Chang, MSEE (CEO of Accompany), Ram Shriram (Founder of Sherpalo), and Wende Hutton, MBA (General Partner, Canaan). The goal of this session was to have this stellar panel identify strengths and weaknesses of the strategies described in each presentation, providing invaluable advice to these budding entrepreneurs.

The organizers of the meeting, Joseph Wu, MD, PhD; Sanjay Malhotra, PhD; Kuldev Singh, MD; Mark Mercola, PhD; and Chaitan Khosla, PhD, are thrilled with the success of this gathering, and are already looking forward to the next iteration, which will be held April 22-23, 2019.

___

Copyright Keystone Symposia, 2018. All rights reserved.

About Keystone Symposia:
Keystone Symposia is a 501(c)(3) nonprofit organization founded in 1972 that convenes 50-60 open, international scientific research conferences each year across the full range of the life sciences – from cardiovascular disease to immunology to neurobiology. The conferences accelerate life science discovery by bringing together and fostering collaboration among the world’s leading and next generation of research scientists.

Visit Keystone Symposia at:

Visit Virtual Keystone Symposia at:

For more videos:

Follow us on Twitter:

Like us on Facebook:

Link to us on LinkedIn:

Outro music:
“Slider” by Blue Dot Sessions (

Continue Reading

Medical Discovery

Virtual Recap Preview: Stanford Drug Discovery Symposium 2018 – Janet Woodcock, MD

Published

on

By



Virtual Recap: Stanford Drug Discovery 2018
Learn more:

On April 23-24,2018 over 550 people gathered at the Li Ka Shing Conference Center to attend the Third Annual Stanford Drug Discovery Symposium. The event featured a broad range of speakers sharing their expertise in the fields of: academic drug discovery, academic-industry collaboration, science policy, publishing, and research funding. On the first day, the packed-house audience was treated to presentations from academic scientists engaged in groundbreaking research that is laying the foundation for future therapeutic approaches. These included Stanford based Nobel Laureate Brian Kobilka, MD and Edgar Engleman, MD; Kathleen Giacomini, PhD, and Kevan Shokat, PhD from UCSF; and Hugh Rosen, MD, PhD, from the Scripps Research Institute.

Later that afternoon, attendees had the rare opportunity to interact with six top pharmaceutical executives and philanthropists: Ken Frazier, CEO of Merck; Robert Bradway, CEO of Amgen; Joseph Jimenez, former CEO of Novartis; Brent Saunders, CEO of Allergan; Patrick Soon-Shiong, MD, CEO of Nantworks; and Sanford Weill, the Chairman Emeritus of Citigroup and CEO of Casa Rosa Ventures. In this “View from the Top” session moderated by Stanford President Marc Tessier-Lavigne, PhD, the panelists offered their perspectives on drug discovery, including: the future of personalized medicine, the importance of focusing on disease prevention rather than treatment, and the concept that drug pricing could eventually be based on treatment outcomes. The first day ended with the presentation of a Lifetime Achievement Award to Roy Vagelos, MD, former CEO of Merck and current Board chair of Regeneron. Dr. Vagelos was acknowledged in part for his role in leveraging the power of the pharmaceutical industry to make a major impact on global health. During his term as Merck CEO, he personally committed to providing the drug Ivermectin free of charge to anyone in the world for the treatment of elephantiasis and river blindness, with the latter having been since eradicated in multiple Central and South American countries due to Dr. Vagelos’ efforts.

The second day of the Symposium opened with a Keynote address from Janet Woodcock, MD, the Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA), who provided a look inside the agency’s new drug regulatory program. This was followed by important presentations about funding priorities from Gary Gibbons, MD, the Director of the National Heart, Lung, and Blood Institute (NHLBI), and Maria Millan, MD, President and CEO of the California Institute for Regenerative Medicine (CIRM). Later, the audience was treated to a panel of editors representing the top publications in biomedical science: the New England Journal of Medicine, Nature Medicine, Science, and the Journal of the American Medical Association. The meeting concluded with a dynamic Shark Tank-style session, in which representatives from eight competitively selected start-up biotechnology companies pitched their ideas to a panel of scientists, venture capitalists, and CEOs. The panelists who provided feedback were: George Scangos, PhD (CEO of Vir), Robert Robbins, MD (President of the University of Arizona), Roy Vagelos, MD, Amy Chang, MSEE (CEO of Accompany), Ram Shriram (Founder of Sherpalo), and Wende Hutton, MBA (General Partner, Canaan). The goal of this session was to have this stellar panel identify strengths and weaknesses of the strategies described in each presentation, providing invaluable advice to these budding entrepreneurs.

The organizers of the meeting, Joseph Wu, MD, PhD; Sanjay Malhotra, PhD; Kuldev Singh, MD; Mark Mercola, PhD; and Chaitan Khosla, PhD, are thrilled with the success of this gathering, and are already looking forward to the next iteration, which will be held April 22-23, 2019.

___

Copyright Keystone Symposia, 2018. All rights reserved.

About Keystone Symposia:
Keystone Symposia is a 501(c)(3) nonprofit organization founded in 1972 that convenes 50-60 open, international scientific research conferences each year across the full range of the life sciences – from cardiovascular disease to immunology to neurobiology. The conferences accelerate life science discovery by bringing together and fostering collaboration among the world’s leading and next generation of research scientists.

Visit Keystone Symposia at:

Visit Virtual Keystone Symposia at:

For more videos:

Follow us on Twitter:

Like us on Facebook:

Link to us on LinkedIn:

Outro music:
“Slider” by Blue Dot Sessions (

Continue Reading

Trending